Could Your MS-Like Leg Symptoms Have Another Cause?
By MS Buddy ·
Summarized from JAMA neurology, Oct 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Research by Yi-Heng Zeng, Xiang Lin and 23 colleagues at Huaqiao University, Fujian Medical University and 5 other institutions in China and Canada.
Key Takeaway
A rare inherited condition can look like MS, so people with unexplained stiff legs and unusual scan results may benefit from asking whether genetic testing is appropriate.
What They Found
Researchers studied 26 people from 11 families and linked changes in a gene called PLAAT4 to a rare condition that mainly affects the spinal cord. Most affected people developed stiff, weak legs that made walking harder. Scans showed a long, matching pattern of damage on both sides of the spinal cord, along with changes in the brain’s white matter, which carries messages between nerve cells. In some family members without symptoms, spinal cord changes appeared before brain changes. Mouse experiments supported the gene’s role in damaging the protective coating around nerves, and blood tests found fat-like substances that may be linked to disability.
Who Should Care and Why
This study matters most to people whose stiff or weak legs have no clear cause, especially if they have been told they might have MS. The condition can resemble MS on a scan, but it has a different cause. Getting the right diagnosis may help people avoid MS treatments that lower the immune system when those treatments are not needed. If this sounds like your situation, ask your neurologist whether your spinal cord scans and family history point to a need for genetic testing. Caregivers may also find it useful to note when walking problems began and whether relatives have had similar symptoms.
Important Considerations
This was a small study of a rare condition, so its findings will not apply to most people with MS-like symptoms. Only four patients were followed over time, making it hard to predict how quickly the condition changes. The blood test finding is not yet a proven way to track the condition, and the study did not test a treatment.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in JAMA neurology by et al.. Reproduced from the PubMed record.
Leukoencephalopathies are clinically and etiologically heterogeneous disorders, and establishing a specific diagnosis remains challenging. Patients with unexplained spastic paraplegia and brain white matter hyperintensities (WMH) may be misdiagnosed as having multiple sclerosis, potentially exposing them to unnecessary immunosuppressive therapy. To define the clinical, radiological, and genetic features of spinal predominant demyelinating leukodystrophy with leg spasticity (SPDMLS). This case series involved participants from 4 tertiary referral hospitals within the China Alliance for Rare Diseases during the period July 2019 to August 2025. The study design integrated clinical evaluations and whole-exome sequencing (WES), as well as targeted plasma lipidomics correlated with SPATAX-EUROSPA disability stages. Variant pathogenicity was evaluated using an oligodendrocyte-specific knock-in mouse model. Participants were patients with unexplained spastic paraplegia and central nervous system (CNS) WMH and available family members, including presymptomatic carriers. WES, genetic characterization, testing. Identification of disease-associated gene and characterization of clinical, radiological, and genetic features of SPDMLS. Twenty-six individuals from 11 unrelated families were included; 4 patients underwent longitudinal follow-up for up to 5 years. Recurrent heterozygous PLAAT4 (phospholipase A and acyltransferase 4) variants (p.I14T and p.A96V) were associated with a novel autosomal dominant leukoencephalopathy, named SPDMLS. Age at onset was 11 to 51 years (median [IQR], 22 [15-29] years), with patients predominantly developing spastic paraplegia. Symbol Digit Modalities Test scores ranged from 11 to 70 in 6 available patients. Magnetic resonance imaging (MRI) demonstrated slow progression with heterogeneous brain WMH and a stereotyped pattern of symmetric, long-segment "girdle-like" spinal cord WMH accompanied by atrophy. Somatosensory- and motor-evoked potentials indicated dysfunction of the dorsal columns and corticospinal tracts, respectively. In presymptomatic carriers, spinal cord signal alterations preceded brain involvement. An oligodendrocyte-specific knock-in mouse model provided in vivo functional evidence supporting a role of PLAAT4 gain-of-function in driving demyelination, informing SPDMLS pathogenesis. Patient plasma lipidomics suggested accumulation of arachidonic acid-related lipids correlating with disability stage. This study found that PLAAT4 variants delineated SPDMLS, a clinically distinct leukodystrophy that should be considered in patients with unexplained spastic paraplegia and CNS WMH. Arachidonic acid-related lipids represent a candidate biomarker for disease progression.
Categories
Explore more research
Related MS research

11/14/2026
An opinion paper explains why MS brain scans can show tissue loss without proving nerve signal failu
Read More
11/15/2026
In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e
Read More
11/15/2026
In 70 people with MS in Brazil, blood tests often showed signs of past viral exposure. Results did n
Read More
11/13/2026
A review compares MS with harmful drug reactions and proposes ways to test how immune genes, lasting
Read More
11/13/2026
This review examines how vitamin D and vitamin A signals shape immune activity in MS and other disea
Read More
11/12/2026
In mice with an MS-like disease, a lab-made protein improved movement and thinking. Researchers also
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
